Factors associated with vancomycin nephrotoxicity in the critically ill

Area of Science:

• Pharmacology
• Nephrology
• Critical Care Medicine

Background:

• Vancomycin is a key antibiotic for methicillin-resistant Staphylococcus aureus (MRSA).
• Increasing MRSA vancomycin resistance necessitates higher drug concentrations.
• Potential for vancomycin nephrotoxicity requires careful evaluation.

Purpose of the Study:

• To investigate the association between elevated vancomycin serum concentrations and acute kidney injury (AKI).
• To assess the safety of more aggressive vancomycin dosing strategies in critically ill patients.

Main Methods:

• Retrospective analysis of vancomycin use over five years.
• Evaluation of new-onset AKI using Risk, Injury, Failure, Loss and End-stage (RIFLE) criteria.
• Multivariate logistic regression to identify AKI predictors.

Main Results:

• 8.8% of patients developed new-onset AKI.
• Significant predictors of AKI included mean trough vancomycin concentration (OR=1.174, P=0.024), APACHE II score (OR=1.141, P=0.012), and concurrent aminoglycoside use (OR=18.896, P=0.002).
• Median vancomycin trough concentration was 16 mg/l.

Conclusions:

• Higher vancomycin trough serum concentrations are linked to increased odds of AKI in critically ill patients.
• Clinical decisions on vancomycin dosing must consider the risk of nephrotoxicity.
• Further research may inform optimized dosing protocols for vancomycin therapy.